Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.
Hasan A, Roeh A, Leucht S, Langguth B, Hansbauer M, Oviedo-Salcedo T, Kirchner SK, Papazova I, Löhrs L, Wagner E, Maurus I, Strube W, Rossner MJ, Wehr MC, Bauer I, Heres S, Leucht C, Kreuzer PM, Zimmermann S, Schneider-Axmann T, Görlitz T, Karch S, Egert-Schwender S, Schossow B, Rothe P, Falkai P.
Hasan A, et al. Among authors: maurus i.
Contemp Clin Trials Commun. 2020 Jan 28;17:100537. doi: 10.1016/j.conctc.2020.100537. eCollection 2020 Mar.
Contemp Clin Trials Commun. 2020.
PMID: 32072071
Free PMC article.